Paul Hudson, Sanofi CEO (Eric Piermont/AFP via Getty Images)
April 11, 2023 07:12 AM EDT
Deals

Ex­tend­ed FTC re­view adds wrin­kle to Sanofi's $2.9B Proven­tion Bio buy­out

Amber Tong

Sanofi is ex­tend­ing the dead­line for its $2.9 bil­lion ac­qui­si­tion of Proven­tion Bio to give an­titrust reg­u­la­tors more time to re­view the deal.

The French …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Biotech seed rounds sink to low­est lev­el in years as in­dus­try slump drags on

Phar­ma's wins and loss­es in Trump's sprawl­ing ex­ec­u­tive or­der on drug prices

US drugs re­ly heav­i­ly on in­gre­di­ents made over­seas, new re­port shows

Sarep­ta los­es CMO to RNA edit­ing up­start; An­oth­er wave of per­son­nel moves at Dyne

Ex­clu­sive: VelaV­i­go inks an­oth­er US biotech deal as Chi­na drug de­vel­op­ment scene booms

sponsored

New York-based part­ner­ship sets the stan­dard for ex­pand­ing clin­i­cal tri­al ac­cess for un­der­served and di­verse ...

A service from the Financial Times